Home › Metastatic Cancer › South Carolina › Myrtle Beach
Metastatic Cancer clinical trials in Myrtle Beach, SC
5 studies for Metastatic Cancer are looking for participants at sites in and around Myrtle Beach (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
RecruitingPhase 1/2
- Avenzo Therapeutics Recruiting Site, Myrtle Beach
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RecruitingPhase 1/2
- Grand Strand Medical Center, Myrtle Beach
- Carolina Urologic Research Center, LLC, Myrtle Beach
- Parkway Surgery Center, Myrtle Beach
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RecruitingPhase 1
- Carolina Urologic Research Center, Myrtle Beach
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
RecruitingPhase 1
- Carolina Urologic Research Center, the START Center for Cancer Research, Myrtle Beach
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
RecruitingPhase 1
- Carolina Urologic Research Center, Myrtle Beach
Metastatic Cancer trials in other cities
- Houston, TX104 studies
- New York City, NY93 studies
- Nashville, TN70 studies
- Boston, MA63 studies
- Los Angeles, CA57 studies
- St. Louis, MO54 studies
- Arlington, VA53 studies
- Philadelphia, PA46 studies
- Chicago, IL45 studies
- San Antonio, TX44 studies
- Washington, DC43 studies
- Dallas, TX42 studies
Other studies in Myrtle Beach
- Prostate Cancer24 studies
- Bladder Cancer10 studies
- Non-Muscle Invasive Bladder Cancer9 studies
- Kidney Cancer (Renal Cell Carcinoma)6 studies
- Urothelial (Transitional Cell) Carcinoma5 studies
- Type 2 Diabetes3 studies
- Castration-Resistant Prostatic Cancer3 studies
- Cancer (all types)3 studies
- Carcinoma in Situ3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.